JP2009504622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009504622A5 JP2009504622A5 JP2008525620A JP2008525620A JP2009504622A5 JP 2009504622 A5 JP2009504622 A5 JP 2009504622A5 JP 2008525620 A JP2008525620 A JP 2008525620A JP 2008525620 A JP2008525620 A JP 2008525620A JP 2009504622 A5 JP2009504622 A5 JP 2009504622A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- psychosis
- dihydrotetrabenazine
- schizophrenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 208000028017 Psychotic disease Diseases 0.000 claims 14
- 201000000980 schizophrenia Diseases 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 5
- 206010012239 Delusion Diseases 0.000 claims 4
- 231100000868 delusion Toxicity 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 208000004547 Hallucinations Diseases 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 201000006347 Intellectual Disability Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010021402 Illogical thinking Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 206010033864 Paranoia Diseases 0.000 claims 1
- 208000027099 Paranoid disease Diseases 0.000 claims 1
- 206010034038 Parotitis Diseases 0.000 claims 1
- 206010034719 Personality change Diseases 0.000 claims 1
- 206010053632 Reactive psychosis Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 201000002545 drug psychosis Diseases 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 230000008451 emotion Effects 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0516167.4A GB0516167D0 (en) | 2005-08-06 | 2005-08-06 | Pharmaceutical compounds |
| GB0516790A GB0516790D0 (en) | 2005-08-16 | 2005-08-16 | Pharmaceutical compounds |
| PCT/GB2006/002936 WO2007017654A1 (en) | 2005-08-06 | 2006-08-04 | 3, hb cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009504622A JP2009504622A (ja) | 2009-02-05 |
| JP2009504622A5 true JP2009504622A5 (enExample) | 2009-09-24 |
Family
ID=37400949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525620A Ceased JP2009504622A (ja) | 2005-08-06 | 2006-08-04 | 医薬化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20110257220A1 (enExample) |
| EP (2) | EP1855677B1 (enExample) |
| JP (1) | JP2009504622A (enExample) |
| KR (1) | KR20080033500A (enExample) |
| AT (2) | ATE415968T1 (enExample) |
| AU (1) | AU2006277753B2 (enExample) |
| CA (1) | CA2620960A1 (enExample) |
| CY (1) | CY1108843T1 (enExample) |
| DE (1) | DE602006004009D1 (enExample) |
| DK (1) | DK1855677T3 (enExample) |
| ES (1) | ES2318771T3 (enExample) |
| HR (1) | HRP20090074T3 (enExample) |
| MX (1) | MX2008001549A (enExample) |
| NZ (1) | NZ566011A (enExample) |
| PL (1) | PL1855677T3 (enExample) |
| PT (1) | PT1855677E (enExample) |
| RS (1) | RS50807B (enExample) |
| RU (1) | RU2407743C2 (enExample) |
| SI (1) | SI1855677T1 (enExample) |
| WO (1) | WO2007017654A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007317242B2 (en) | 2006-11-08 | 2013-08-01 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
| US8008500B2 (en) | 2007-06-08 | 2011-08-30 | General Electric Company | Intermediates useful for making tetrabenazine compounds |
| US8053578B2 (en) | 2007-11-29 | 2011-11-08 | General Electric Company | Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes |
| GB0810857D0 (en) * | 2008-06-13 | 2008-07-23 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| GB2463451A (en) | 2008-09-08 | 2010-03-17 | Cambridge Lab | 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia |
| GB2463283A (en) * | 2008-09-08 | 2010-03-10 | Cambridge Lab | 3,11b-cis-dihydrotetrabenazine for use in treating asthma |
| WO2011153157A2 (en) | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| US9658363B2 (en) | 2011-04-01 | 2017-05-23 | 3M Innovative Properties Company | Films including triazine-based ultraviolet absorbers |
| MX2016009817A (es) | 2014-01-27 | 2017-02-28 | Auspex Pharmaceuticals Inc | Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2. |
| CN106061506A (zh) * | 2014-02-07 | 2016-10-26 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
| LT3875459T (lt) | 2015-10-30 | 2024-02-26 | Neurocrine Biosciences, Inc. | Valbenazino dihidrochlorido druskos ir jų polimorfai |
| CA3009169A1 (en) | 2015-12-23 | 2017-06-29 | Neurocrine Biosciences, Inc. | Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
| JP2020500875A (ja) * | 2016-12-02 | 2020-01-16 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
| JP7090151B2 (ja) | 2017-01-27 | 2022-06-23 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| MA50175B1 (fr) | 2017-09-21 | 2025-05-30 | Neurocrine Biosciences, Inc. | Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| AU2017435893B2 (en) | 2017-10-10 | 2023-06-29 | Neurocrine Biosciences, Inc | Methods for the administration of certain VMAT2 inhibitors |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| SG11202100303QA (en) | 2018-08-15 | 2021-02-25 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2843591A (en) * | 1958-07-15 | Method for preparing same | ||
| US2830993A (en) | 1958-04-15 | Quinolizine derivatives | ||
| CA2058640A1 (en) * | 1991-01-25 | 1992-07-26 | Richard R. Scherschlicht | Tricyclic pyridone derivative |
| US6087376A (en) * | 1997-02-05 | 2000-07-11 | University Of Kentucky Research Foundation | Use of lobeline compounds in the treatment of central nervous system diseases and pathologies |
| FR2770215B1 (fr) * | 1997-10-28 | 2000-01-14 | Pf Medicament | Derives d'aminomethyl-benzo[a]quinolizidine, leur preparation et leur application en therapeutique pour les maladies neurodegeneratives |
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
-
2006
- 2006-08-04 US US11/997,591 patent/US20110257220A1/en not_active Abandoned
- 2006-08-04 RU RU2008108623/04A patent/RU2407743C2/ru not_active IP Right Cessation
- 2006-08-04 CA CA002620960A patent/CA2620960A1/en not_active Abandoned
- 2006-08-04 ES ES06765238T patent/ES2318771T3/es active Active
- 2006-08-04 SI SI200630210T patent/SI1855677T1/sl unknown
- 2006-08-04 MX MX2008001549A patent/MX2008001549A/es active IP Right Grant
- 2006-08-04 PL PL06765238T patent/PL1855677T3/pl unknown
- 2006-08-04 WO PCT/GB2006/002936 patent/WO2007017654A1/en not_active Ceased
- 2006-08-04 AU AU2006277753A patent/AU2006277753B2/en not_active Expired - Fee Related
- 2006-08-04 NZ NZ566011A patent/NZ566011A/en not_active IP Right Cessation
- 2006-08-04 HR HR20090074T patent/HRP20090074T3/xx unknown
- 2006-08-04 AT AT06765238T patent/ATE415968T1/de active
- 2006-08-04 RS RSP-2009/0055A patent/RS50807B/sr unknown
- 2006-08-04 AT AT08170385T patent/ATE534391T1/de active
- 2006-08-04 EP EP06765238A patent/EP1855677B1/en active Active
- 2006-08-04 KR KR1020087005308A patent/KR20080033500A/ko not_active Withdrawn
- 2006-08-04 PT PT06765238T patent/PT1855677E/pt unknown
- 2006-08-04 DK DK06765238T patent/DK1855677T3/da active
- 2006-08-04 JP JP2008525620A patent/JP2009504622A/ja not_active Ceased
- 2006-08-04 DE DE602006004009T patent/DE602006004009D1/de active Active
- 2006-08-04 EP EP08170385A patent/EP2050451B1/en active Active
-
2009
- 2009-02-26 CY CY20091100221T patent/CY1108843T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009504622A5 (enExample) | ||
| JP2012520249A5 (enExample) | ||
| JP2009533356A5 (enExample) | ||
| PH12012501222A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| JP2005506370A5 (enExample) | ||
| BR112015008962A2 (pt) | silicato de zircônio microporoso para o tratamento de hipercalemia | |
| MX2012012952A (es) | Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina. | |
| RU2008108623A (ru) | Фармацевтические соединения | |
| WO2010080452A3 (en) | siRNA COMPOUNDS AND METHODS OF USE THEREOF | |
| EP2582676A4 (en) | POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS | |
| MX2009004362A (es) | Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk. | |
| JP2013507352A5 (enExample) | ||
| PH12018502445A1 (en) | Compositions and methods for treating negative symptoms in non-schizophrenic patients | |
| JP2012521966A5 (enExample) | ||
| JP2014508758A5 (enExample) | ||
| JP2007516193A5 (enExample) | ||
| JP2017105861A5 (enExample) | ||
| ATE357453T1 (de) | Comt-inhibitoren | |
| JP2009501202A5 (enExample) | ||
| JP2007504168A5 (enExample) | ||
| JP2009500420A5 (enExample) | ||
| WO2016033432A9 (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| Tészás et al. | Expanding the clinical spectrum of MYCN‐related Feingold syndrome | |
| NZ597657A (en) | Use sulphur particles less than 300 microns and sodium lignin sulfonate for treating diseases casused by microbial pathogenic infections | |
| PL1638559T3 (pl) | Zastosowanie pirazolopirydyn w leczeniu deficytów poznawczych |